Op­divo in­di­ca­tion

Pharmacy Daily - - Front page -

BRIS­TOL-MY­ERS Squibb today an­nounced that pa­tients with re­cur­rent or metastatic squa­mous cell car­ci­noma of the head and neck will have ac­cess to Op­divo (nivolumab) via the Phar­ma­ceu­ti­cal Ben­e­fits Scheme (PBS) from 01 Aug.

The monother­apy au­thor­ity re­quired stream­lined PBS list­ing rep­re­sents the first time pa­tients with re­cur­rent or metastatic head and neck can­cer will have PBS re­im­bursed ac­cess to an im­munoon­col­ogy ther­apy.

This will pro­vide health­care pro­fes­sion­als and pa­tients with a new and af­ford­able treat­ment op­tion for this hard-to-treat can­cer that of­ten re­quires a mul­ti­fac­eted ap­proach of surgery, ra­dio­ther­apy, chemo­ther­apy and sup­port­ive care, BMS said.

Ap­proved PI is at tga.gov.au.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.